Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of engulfment of apoptotic cell. [GO:kmv, GOC:TermGenie, PMID:19402756]
The regulation of engulfment of apoptotic cells, a critical process in tissue homeostasis, involves a complex interplay of signaling pathways, receptors, and intracellular mediators. It is essential for the timely and efficient removal of dying cells to prevent inflammation and maintain tissue integrity.
The process begins with the recognition of apoptotic cells by neighboring cells or professional phagocytes, such as macrophages. This recognition is mediated by a variety of "eat me" signals displayed on the surface of apoptotic cells, including phosphatidylserine (PS) exposure, which is normally located on the inner leaflet of the plasma membrane but flips to the outer leaflet during apoptosis. Other "eat me" signals include calreticulin, thrombospondin, and oxidized low-density lipoprotein (oxLDL).
These signals are detected by specific receptors on phagocytes. Among the most well-studied receptors are:
* **Phosphatidylserine receptors:** These include TIM-4, BAI1, and stabilin-2, which directly bind PS exposed on apoptotic cells.
* **Complement receptors:** Receptors like CR3 (CD11b/CD18) recognize complement proteins that bind to apoptotic cells.
* **Scavenger receptors:** Receptors like SR-A and CD36 recognize various ligands, including oxLDL, that can be displayed on apoptotic cells.
* **Other receptors:** Additional receptors, like CD14, lectins, and integrins, may contribute to apoptotic cell recognition.
Upon receptor engagement, intracellular signaling pathways are activated, leading to the recruitment and activation of downstream proteins. These pathways include:
* **PI3K/Akt pathway:** This pathway promotes cell survival and phagocytic activity, contributing to the efficient engulfment of apoptotic cells.
* **Rho GTPase pathway:** This pathway regulates cytoskeletal rearrangements and membrane protrusions necessary for phagocytosis.
* **Rac1 pathway:** This pathway controls actin polymerization and the formation of phagocytic cups that engulf apoptotic cells.
* **Small GTPases:** Other small GTPases, like Cdc42, also contribute to cytoskeletal rearrangements.
The activation of these signaling pathways ultimately leads to the engulfment of apoptotic cells. Phagocytes extend pseudopodia, membrane protrusions, that enclose the apoptotic cell, forming a phagocytic cup. The apoptotic cell is then internalized within a phagosome, a membrane-bound vesicle.
Once inside the phagocyte, the apoptotic cell is degraded by lysosomal enzymes. This degradation process ensures the safe removal of the apoptotic cell's components and prevents the release of potentially damaging cellular contents.
The regulation of engulfment is tightly controlled, ensuring proper clearance of apoptotic cells and preventing the development of autoimmune diseases or inflammation. Dysregulation of engulfment can contribute to various pathological conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.
Therefore, understanding the intricate mechanisms involved in apoptotic cell engulfment is crucial for developing new therapeutic strategies for treating these conditions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Polyunsaturated fatty acid lipoxygenase ALOX15 | A polyunsaturated fatty acid lipoxygenase ALOX15 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P16050] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
chloroxine | chloroxine : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp. | monohydroxyquinoline; organochlorine compound | antibacterial agent; antifungal drug; antiseborrheic |
hexylresorcinol | resorcinols | ||
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide | 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines. | benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
masoprocol | nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata) | catechols; lignan; tetrol | antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite |
probucol | probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood. Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | dithioketal; polyphenol | anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
tetrabromobisphenol a | 3,3',5,5'-tetrabromobisphenol A : A bromobisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups and the phenyl rings are substituted by bromo groups at positions 2, 2', 6 and 6'. It is a brominated flame retardant. tetrabromobisphenol A: a brominated flame retardant | brominated flame retardant; bromobisphenol | |
phenidone | phenidone: photographic developer; RN given refers to parent cpd; structure | ||
2-bromophenol | bromophenol : A halophenol that is any phenol containing one or more covalently bonded bromine atoms. | bromophenol | marine metabolite |
4-bromophenol | 4-bromophenol : A bromophenol containing only hydroxy and bromo substituents that are para to one another. | bromophenol | human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite |
indolizine | indolizines; mancude organic heterobicyclic parent | ||
3-hydroxyflavone | 3-hydroxyflavone: structure given in first source flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone. | flavonols; monohydroxyflavone | |
3-bromophenol | |||
2,6-dibromophenol | 2,6-dibromophenol : A dibromophenol that is phenol in which both of the hydrogens that are ortho to the phenolic hydroxy group have been replaced by bromines. | bromohydrocarbon; dibromophenol | marine metabolite |
2,4-dibromophenol | 2,4-dibromophenol : A bromophenol that is phenol in which the hydrogens at positions 2 and 4 have been replaced by bromines. | brominated flame retardant; bromophenol; dibromobenzene | marine metabolite |
zileuton | 1-benzothiophenes; ureas | anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug | |
6-hydroxyflavone | 6-hydroxyflavone: antioxidant; structure in first source | hydroxyflavonoid | |
puupehenone | |||
l 656224 | L 656224: structure given in first source | ||
moracin c | benzofurans | ||
pd 146176 | PD-146176 : An organic heterotetracyclic compound that is 1H-indole which is ortho-fused to a 2H-1-benzothiopyran group at positions 2-3. It is an inhibitor of 15-lipoxygenase that limits atherosclerotic lesion development in rabbits. | organic heterotetracyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound | antiatherogenic agent; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; ferroptosis inhibitor |
boswellic acid | |||
2-(4-chlorophenyl)-5-(methylamino)-4-oxazolecarbonitrile | 1,3-oxazoles | ||
3,6-dihydroxyflavone | 3,6-dihydroxyflavone: induces apoptosis in leukemia HL-60 cells; structure in first source | ||
aurapten | aurapten: RN refers to (E)-isomer; structure given in first source auraptene : A member of the class of coumarins that is umbelliferone in which the phenolic hydrogen has been replaced by a geranyl group. Ii is isolated from several edible fruits and vegetables and exhibits a variety of therapeutic properties. | coumarins; monoterpenoid | antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; dopaminergic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; gamma-secretase modulator; gastrointestinal drug; hepatoprotective agent; matrix metalloproteinase inhibitor; neuroprotective agent; plant metabolite; PPARalpha agonist; vulnerary |
umbelliprenin | umbelliprenin: RN given refers to cpd with unspecified isomeric designation | terpene lactone | |
4-fluorobenzoic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthalenes | ||
4-methoxybenzoic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | methoxybenzoic acid | ||
4-bromobenzoic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthalenes | ||
2-benzofurancarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthalenes | ||
3,5-dibromo-2-(2,4-dibromophenoxy)phenol | 3,5-dibromo-2-(2,4-dibromophenoxy)phenol: isolated from the marine sponge Callyspongidae; inhibits contraction of smooth muscle in ileum; structure in first source | ||
4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]-2-butyn-1-ol | naphthalenes | ||
1-phenyl-2-[[4-(trifluoromethyl)phenyl]methylthio]imidazole | imidazoles | ||
4-chlorobenzoic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthalenes | ||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
luteolin | 3'-hydroxyflavonoid; tetrahydroxyflavone | angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist | |
15-keto-5,8,11,13-eicosatetraenoic acid | 15-keto-5,8,11,13-eicosatetraenoic acid: RN given refers to (E,Z,Z,Z)-isomer; RN for cpd without isomeric designation not available 3/88 15-oxo-ETE : An oxoicosatetraenoic acid having (5Z,8Z,11Z,13E) double bond stereochemistry, and an oxo group in position 15. | oxoicosatetraenoic acid | human metabolite |
baicalein | trihydroxyflavone | angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger | |
fisetin | 3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone | anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite | |
mangostin | alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities. mangostin: xanthone from rind of Garcinia mangostana Linn. fruit | aromatic ether; phenols; xanthones | antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite |
daidzein | 7-hydroxyisoflavones | antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite | |
caffeic acid phenethyl ester | phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component. | alkyl caffeate ester | anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent |
7-hydroxyflavone | 7-hydroxyflavone : A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group. | hydroxyflavonoid | |
5-oxo-6,8,11,14-eicosatetraenoic acid | 5-ketoeicosatetraenoic acid: a nonenzymatic rearrangement product of leukotriene A4; structure given in first source 5-oxo-ETE : An oxoicosatetraenoic acid having a 5-oxo group; and (6E)-, (8Z), (11Z)- and (14Z)-double bonds. | oxoicosatetraenoic acid | human metabolite; immunomodulator; mouse metabolite |
6,7,4'-trihydroxyisoflavone | 4',6,7-trihydroxyisoflavone : A hydroxyisoflavone that is daidzein bearing an additional hydroxy substituent at position 6. 6,7,4'-trihydroxyisoflavone: structure in first source | 7-hydroxyisoflavones | anti-inflammatory agent; antimutagen; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite; PPARalpha agonist; PPARgamma agonist |
7-hydroxyisoflavone | 7-hydroxyisoflavone : The simplest member of the class of 7-hydroxyisoflavones that is isoflavone with a hydroxy substituent at position 7. 7-hydroxyisoflavone: effective against, Enterovirus 71; structure in first source | 7-hydroxyisoflavones | EC 1.14.14.14 (aromatase) inhibitor; metabolite |
3,7-dihydroxyflavone | 3,7-dihydroxyflavone: structure in first source 7-hydroxyflavonol : Any flavonol carrying a 7-hydroxy substituent. | hydroxyflavan | |
13-oxo-9,11-octadecadienoic acid | 13-oxo-9Z,11E-ODE : An oxooctadecadienoic acid that consists of 9Z,11E-octadecadienoic acid bearing an additional 13-keto substituent. In addtion it has been found as a natural product found in Carthamus oxyacantha. | 13-oxo-9,11-octadecadienoic acid | metabolite; mouse metabolite |
dysidenin | dysidenin : A secondary carboxamide resulting from the formal condensation of the carboxy group of (4S)-5,5,5-trichloro-N-methyl-N-[(3S)-4,4,4-trichloro-3-methylbutanoyl]-L-leucine with the amino group of (1S)-1-(1,3-thiazol-2-yl)ethanamine. It is a marine metabolite initially isolated from the sponge dysidea herbacea. dysidenin: structure given in first source; from the sponge Dysidea herbacea; RN given refers to (2S-(N(R*),2R*(R*),4R*))-isomer; RN for cpd without isomeric designation not avail 5/90 | 1,3-thiazoles; organochlorine compound; secondary carboxamide; tertiary carboxamide | animal metabolite; marine metabolite; toxin |
jaspaquinol | jaspaquinol: structure in first source | ||
halisulfate 1 | halisulfate 1: an isocitrate lyase inhibitor sesterterpene sulfate from sponge, Hippospongia sp.; structure in first source | organic molecular entity | metabolite |
N-[4-cyano-2-(1-naphthalenyl)-5-oxazolyl]acetamide | naphthalenes | ||
5-amino-2-(1-naphthalenyl)-4-oxazolecarbonitrile | naphthalenes | ||
4-(dimethylamino)benzoic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthalenes | ||
2-methoxybenzoic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | methoxybenzoic acid | ||
2-naphthalenecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthoic acid | ||
1H-imidazole-5-carboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | naphthalenes | ||
1H-indole-4-carboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester | indolyl carboxylic acid | ||
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide | hydroxyquinoline | ||
ML355 | ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis. ML355: 12-Lipoxygenase inhibitor | benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide | EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor |